ESMO Virtual Congress 2020: Clinical Benefit In Biomarker-Positive Patients with Locally Advanced or Metastatic Solid Tumors Treated with The PARP1/2 inhibitor Pamiparib in Combination with Low-Dose Temozolomide

(UroToday.com) In this presentation, Dr. Emiliano Calvo presented exploratory biomarker data from the ongoing phase 1b study (NCT03150810) of the PARP 1/2 inhibitor pamiparib in combination with low dose temozolomide in solid tumors. The treatment schema is shown below.